| scholarly article | Q13442814 |
| P50 | author | Rashmi Kothary | Q42739932 |
| Melissa Bowerman | Q56422647 | ||
| P2093 | author name string | Justin G Boyer | |
| Carrie L Anderson | |||
| Lyndsay M Murray | |||
| P2860 | cites work | Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase | Q22010473 |
| Spinal cord injury: a systematic review of current treatment options | Q24631225 | ||
| Cofilin phosphorylation and actin cytoskeletal dynamics regulated by rho- and Cdc42-activated LIM-kinase 2 | Q24670491 | ||
| Characterization of a novel cofilin isoform that is predominantly expressed in mammalian skeletal muscle | Q28116417 | ||
| Development of the vertebrate neuromuscular junction | Q28141504 | ||
| Distinct roles of nerve and muscle in postsynaptic differentiation of the neuromuscular synapse | Q28185780 | ||
| Patterning of muscle acetylcholine receptor gene expression in the absence of motor innervation | Q28511900 | ||
| Muscle deficiency and neonatal death in mice with a targeted mutation in the myogenin gene | Q28592173 | ||
| Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase) | Q28609825 | ||
| Identification and characterization of a spinal muscular atrophy-determining gene | Q29547495 | ||
| Regulation of actin dynamics through phosphorylation of cofilin by LIM-kinase | Q29614246 | ||
| The role of the Rho GTPases in neuronal development | Q29616295 | ||
| A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy | Q29617367 | ||
| A novel method for oral delivery of drug compounds to the neonatal SMNDelta7 mouse model of spinal muscular atrophy | Q30488346 | ||
| Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy | Q33588368 | ||
| Mouse survival motor neuron alleles that mimic SMN2 splicing and are inducible rescue embryonic lethality early in development but not late | Q33797677 | ||
| A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. | Q33864982 | ||
| Prospects for the gene therapy of spinal muscular atrophy | Q34165703 | ||
| Temporal requirement for high SMN expression in SMA mice | Q34192528 | ||
| Compartmental neurodegeneration and synaptic plasticity in the Wld(s) mutant mouse | Q34325139 | ||
| The survival motor neuron protein in spinal muscular atrophy | Q34435656 | ||
| Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension | Q35583736 | ||
| Severe neuromuscular denervation of clinically relevant muscles in a mouse model of spinal muscular atrophy | Q35605208 | ||
| The relationship of neuromuscular synapse elimination to synaptic degeneration and pathology: insights from WldS and other mutant mice | Q35700902 | ||
| Axon retraction and degeneration in development and disease | Q36196519 | ||
| Axon degeneration mechanisms: commonality amid diversity | Q36285969 | ||
| Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos | Q36578997 | ||
| SMN complex localizes to the sarcomeric Z-disc and is a proteolytic target of calpain | Q36934614 | ||
| Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy | Q37294764 | ||
| Multiple roles of HDAC inhibition in neurodegenerative conditions. | Q37407855 | ||
| Future possibilities in glaucoma therapy | Q37803525 | ||
| Therapeutics that directly increase SMN expression to treat spinal muscular atrophy | Q37804700 | ||
| Rho-kinase: important new therapeutic target in cardiovascular diseases | Q37881804 | ||
| Agrin triggers the clustering of raft-associated acetylcholine receptors through actin cytoskeleton reorganization | Q39552157 | ||
| The Rho family G proteins play a critical role in muscle differentiation | Q39574637 | ||
| A critical smn threshold in mice dictates onset of an intermediate spinal muscular atrophy phenotype associated with a distinct neuromuscular junction pathology. | Q39688596 | ||
| Modulation of acto-myosin contractility in skeletal muscle myoblasts uncouples growth arrest from differentiation | Q40536157 | ||
| Regulation of murine survival motor neuron (Smn) protein levels by modifying Smn exon 7 splicing | Q40765994 | ||
| Correlation between severity and SMN protein level in spinal muscular atrophy | Q41102726 | ||
| Rho family GTP-binding proteins in growth cone signalling | Q41353297 | ||
| The neurobiology of childhood spinal muscular atrophy. | Q41489423 | ||
| Pre-symptomatic development of lower motor neuron connectivity in a mouse model of severe spinal muscular atrophy | Q43932877 | ||
| Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina | Q43943286 | ||
| Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study | Q44200627 | ||
| Rho-kinase inhibitor improves increased vascular resistance and impaired vasodilation of the forearm in patients with heart failure | Q46520759 | ||
| Selective vulnerability of motor neurons and dissociation of pre- and post-synaptic pathology at the neuromuscular junction in mouse models of spinal muscular atrophy | Q46861362 | ||
| Molecular mechanism for the regulation of rho-kinase by dimerization and its inhibition by fasudil | Q46986482 | ||
| Loss of myogenin in postnatal life leads to normal skeletal muscle but reduced body size. | Q47353891 | ||
| SMN, profilin IIa and plastin 3: a link between the deregulation of actin dynamics and SMA pathogenesis. | Q48586391 | ||
| Effects of the compact mutant myostatin allele Mstn (Cmpt-dl1Abc) introgressed into a high growth mouse line on skeletal muscle cellularity. | Q50761670 | ||
| Fine regulation of RhoA and Rock is required for skeletal muscle differentiation. | Q50942239 | ||
| Morphological types of motor nerve terminals in rat hindlimb muscles, possibly innervating different muscle fiber types. | Q50963985 | ||
| Density, calibre and ramification of muscle capillaries are altered in a mouse model of severe spinal muscular atrophy. | Q51837710 | ||
| The developmental pattern of myotubes in spinal muscular atrophy indicates prenatal delay of muscle maturation. | Q51932605 | ||
| The role of the cytoskeleton in neuromuscular junction formation. | Q51998378 | ||
| Rho-kinase inactivation prolongs survival of an intermediate SMA mouse model. | Q52598269 | ||
| The spinal muscular atrophy disease protein SMN is linked to the Rho-kinase pathway via profilin. | Q54560146 | ||
| Reversible molecular pathology of skeletal muscle in spinal muscular atrophy | Q57389994 | ||
| Developing standard procedures for pre-clinical efficacy studies in mouse models of spinal muscular atrophy | Q60215160 | ||
| Reduced survival motor neuron (Smn) gene dose in mice leads to motor neuron degeneration: an animal model for spinal muscular atrophy type III | Q60215386 | ||
| Smn depletion alters profilin II expression and leads to upregulation of the RhoA/ROCK pathway and defects in neuronal integrity | Q81303651 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | spinal muscular atrophy | Q580290 |
| muscular atrophy | Q2844600 | ||
| P304 | page(s) | 24 | |
| P577 | publication date | 2012-03-07 | |
| P1433 | published in | BMC Medicine | Q4835947 |
| P1476 | title | Fasudil improves survival and promotes skeletal muscle development in a mouse model of spinal muscular atrophy | |
| P478 | volume | 10 |
| Q51025979 | A-44G transition in SMN2 intron 6 protects patients with spinal muscular atrophy. |
| Q49874005 | Advances in spinal muscular atrophy therapeutics |
| Q35167319 | Advances in therapeutic development for spinal muscular atrophy |
| Q50052600 | Advances in therapy for spinal muscular atrophy: promises and challenges. |
| Q38668630 | Advances in understanding the role of disease-associated proteins in spinal muscular atrophy. |
| Q38530085 | Chatting with the neighbors: crosstalk between Rho-kinase (ROCK) and other signaling pathways for treatment of neurological disorders. |
| Q35707832 | Disease mechanisms and therapeutic approaches in spinal muscular atrophy |
| Q39092025 | Diverse role of survival motor neuron protein |
| Q35006731 | Drug repositioning for orphan genetic diseases through Conserved Anticoexpressed Gene Clusters (CAGCs) |
| Q89477851 | Drug treatment for spinal muscular atrophy types II and III |
| Q92262692 | Effect of Fasudil on remyelination following cuprizone-induced demyelination |
| Q33615182 | Effect of genetic background on the phenotype of the Smn2B/- mouse model of spinal muscular atrophy |
| Q33578135 | Emerging therapies and challenges in spinal muscular atrophy |
| Q34760255 | Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug-like compounds |
| Q30702451 | Established Stem Cell Model of Spinal Muscular Atrophy Is Applicable in the Evaluation of the Efficacy of Thyrotropin-Releasing Hormone Analog. |
| Q41378115 | Fasudil, a clinically safe ROCK inhibitor, decreases disease burden in a Cbl/Cbl-b deficiency-driven murine model of myeloproliferative disorders |
| Q37327385 | Fasudil, a rho kinase inhibitor, limits motor neuron loss in experimental models of amyotrophic lateral sclerosis |
| Q34342044 | GEMINs: potential therapeutic targets for spinal muscular atrophy? |
| Q36302096 | Genetic inhibition of JNK3 ameliorates spinal muscular atrophy |
| Q55369340 | Interventions Targeting Glucocorticoid-Krüppel-like Factor 15-Branched-Chain Amino Acid Signaling Improve Disease Phenotypes in Spinal Muscular Atrophy Mice. |
| Q38441280 | Investigational therapies for the treatment of spinal muscular atrophy. |
| Q36142393 | Low levels of Survival Motor Neuron protein are sufficient for normal muscle function in the SMNΔ7 mouse model of SMA. |
| Q91706732 | Lowering EphA4 Does Not Ameliorate Disease in a Mouse Model for Severe Spinal Muscular Atrophy |
| Q44310626 | Modifying expression of EphA4 and its downstream targets improves functional recovery after stroke |
| Q92503428 | Modulation of Agrin and RhoA Pathways Ameliorates Movement Defects and Synapse Morphology in MYO9A-Depleted Zebrafish |
| Q26752798 | Molecular Mechanisms of Neurodegeneration in Spinal Muscular Atrophy |
| Q92510092 | Motor neuron biology and disease: A current perspective on infantile-onset spinal muscular atrophy |
| Q38197609 | Neurodegeneration in spinal muscular atrophy: from disease phenotype and animal models to therapeutic strategies and beyond |
| Q38060658 | Neuroproteomics approach and neurosystems biology analysis: ROCK inhibitors as promising therapeutic targets in neurodegeneration and neurotrauma |
| Q38140727 | New strategies in the management of Guillain-Barré syndrome. |
| Q51204048 | Oligodendrocyte development and CNS myelination are unaffected in a mouse model of severe spinal muscular atrophy. |
| Q48144714 | Overview of Current Drugs and Molecules in Development for Spinal Muscular Atrophy Therapy |
| Q58764859 | Pharmacological c-Jun NH-Terminal Kinase (JNK) Pathway Inhibition Reduces Severity of Spinal Muscular Atrophy Disease in Mice |
| Q45350511 | Plastin 3 ameliorates spinal muscular atrophy via delayed axon pruning and improves neuromuscular junction functionality. |
| Q42069362 | Proteomic mapping of differentially vulnerable pre-synaptic populations identifies regulators of neuronal stability in vivo |
| Q93355206 | RNA Splicing and Disease: Animal Models to Therapies |
| Q34103656 | ROCK inhibition as a therapy for spinal muscular atrophy: understanding the repercussions on multiple cellular targets |
| Q64111651 | ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis |
| Q34148669 | Rac1 at the crossroad of actin dynamics and neuroinflammation in Amyotrophic Lateral Sclerosis |
| Q37100895 | Restoration of SMN to Emx-1 expressing cortical neurons is not sufficient to provide benefit to a severe mouse model of Spinal Muscular Atrophy |
| Q38562045 | Review of Spinal Muscular Atrophy (SMA) for Prenatal and Pediatric Genetic Counselors |
| Q37614522 | Rho Kinase Inhibition with Fasudil in the SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis-Symptomatic Treatment Potential after Disease Onset |
| Q38260925 | Rho Kinase and Dopaminergic Degeneration: A Promising Therapeutic Target for Parkinson's Disease |
| Q46872819 | Rho kinase inhibition modulates microglia activation and improves survival in a model of amyotrophic lateral sclerosis. |
| Q34312156 | SMN-inducing compounds for the treatment of spinal muscular atrophy |
| Q28536678 | Small molecule suppressors of Drosophila kinesin deficiency rescue motor axon development in a zebrafish model of spinal muscular atrophy |
| Q38489298 | Spinal muscular atrophy--recent therapeutic advances for an old challenge. |
| Q38123249 | Spinal muscular atrophy: a motor neuron disorder or a multi-organ disease? |
| Q26861377 | Spinal muscular atrophy: development and implementation of potential treatments |
| Q26824894 | Spinal muscular atrophy: from gene discovery to clinical trials |
| Q35029616 | Spinal muscular atrophy: from tissue specificity to therapeutic strategies |
| Q35340133 | Spinal muscular atrophy: journeying from bench to bedside |
| Q39125261 | Supraphysiological expression of survival motor neuron protein from an adenovirus vector does not adversely affect cell function. |
| Q39274901 | The Actin Cytoskeleton in SMA and ALS: How Does It Contribute to Motoneuron Degeneration? |
| Q89965003 | The Need for SMN-Independent Treatments of Spinal Muscular Atrophy (SMA) to Complement SMN-Enhancing Drugs |
| Q34297709 | The rho kinase inhibitor Y-27632 improves motor performance in male SOD1(G93A) mice |
| Q36222798 | The role of Rho/Rho-kinase pathway and the neuroprotective effects of fasudil in chronic cerebral ischemia. |
| Q38471353 | The sarcomeric M-region: a molecular command center for diverse cellular processes |
| Q41440571 | Therapeutic strategies for spinal muscular atrophy: SMN and beyond. |
| Q34296140 | Therapeutic strategies for the treatment of spinal muscular atrophy. |
| Q36014761 | Therapy development for spinal muscular atrophy in SMN independent targets. |
Search more.